Scynexis (SCYX) Tops Q2 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Scynexis (SCYX) Tops Q2 EPS by 24c

SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 15, 2022 7:00 AM EDT

BREXAFEMME® (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand BREXAFEMMEs labelling to include the prevention of recurrent vulvovaginal candidiasis (RVVC); the FDA assigned a target PDUFA action date of November 30, 2022 for this additional indication.Enrollment has begun in two Phase 3 trials: the MARIO study is evaluating ibrexafungerp as an oral... More